The nephrotoxicity of antimicrobial agents (second of three parts).
D000617:Aminoglycosides / Q000009:adverse effects; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000378:metabolism / Q000627:therapeutic use; D001424:Bacterial Infections / Q000188:drug therapy; D004195:Disease Models, Animal; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D005919:Glomerular Filtration Rate; D006168:Guinea Pigs; D006207:Half-Life; D006801:Humans; D007668:Kidney / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D007674:Kidney Diseases / Q000139:chemically induced* / Q000503:physiopathology; D011113:Polymyxins / Q000009:adverse effects; D011817:Rabbits; D051381:Rats; D013754:Tetracyclines / Q000009:adverse effects; D014640:Vancomycin / Q000009:adverse effects
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D011113:Polymyxins; D013754:Tetracyclines; D014640:Vancomycin